U.S. Oncology Molecular Diagnostics Market Size, Share, and Trends 2024 to 2033

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis 

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on U.S. Oncology Molecular Diagnostics Market 

5.1. COVID-19 Landscape: U.S. Oncology Molecular Diagnostics Industry Impact

5.2. COVID 19 - Impact Assessment for the Industry

5.3. COVID 19 Impact: U.S  Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. U.S. Oncology Molecular Diagnostics Market, By Type

8.1. U.S. Oncology Molecular Diagnostics Market Revenue and Volume, by Type, 2024-2033

8.1.1 Breast Cancer

8.1.1.1. Market Revenue and Volume Forecast (2021-2033)

8.1.2. Liver Cancer

8.1.2.1. Market Revenue and Volume Forecast (2021-2033)

8.1.3. Prostate Cancer

8.1.3.1. Market Revenue and Volume Forecast (2021-2033)

8.1.4. Colorectal Cancer

8.1.4.1. Market Revenue and Volume Forecast (2021-2033)

8.1.5. Cervical Cancer

8.1.5.1. Market Revenue and Volume Forecast (2021-2033)

8.1.6. Lung Cancer

8.1.6.1. Market Revenue and Volume Forecast (2021-2033)

8.1.7. Blood Cancer

8.1.7.1. Market Revenue and Volume Forecast (2021-2033)

8.1.8. Kidney Cancer

8.1.8.1. Market Revenue and Volume Forecast (2021-2033)

8.1.9. Other Cancer

8.1.9.1. Market Revenue and Volume Forecast (2021-2033)

Chapter 9. U.S. Oncology Molecular Diagnostics Market, By Technology

9.1. U.S. Oncology Molecular Diagnostics Market Revenue and Volume, by Technology, 2024-2033

9.1.1. PCR

9.1.1.1. Market Revenue and Volume Forecast (2021-2033)

9.1.2. Sequencing

9.1.2.1. Market Revenue and Volume Forecast (2021-2033)

9.1.3. In Situ Hybridization

9.1.3.1. Market Revenue and Volume Forecast (2021-2033)

9.1.4. INAAT

9.1.4.1. Market Revenue and Volume Forecast (2021-2033)

9.1.5. Chips and Microarrays

9.1.5.1. Market Revenue and Volume Forecast (2021-2033)

9.1.6. Mass Spectrometry

9.1.56.1. Market Revenue and Volume Forecast (2021-2033)

9.1.7. TMA

9.1.7.1. Market Revenue and Volume Forecast (2021-2033)

9.1.8. Others

9.1.8.1. Market Revenue and Volume Forecast (2021-2033)

Chapter 10. U.S. Oncology Molecular Diagnostics Market, By Product 

10.1. U.S. Oncology Molecular Diagnostics Market Revenue and Volume, by Product, 2024-2033

10.1.1. Reagents

10.1.1.1. Market Revenue and Volume Forecast (2021-2033)

10.1.2. Instruments

10.1.2.1. Market Revenue and Volume Forecast (2021-2033)

10.1.3. Others

10.1.3.1. Market Revenue and Volume Forecast (2021-2033)

Chapter 11. U.S. Oncology Molecular Diagnostics Market, U.S  Estimates and Trend Forecast

11.1. U.S

11.1.1. Market Revenue and Volume Forecast, by Type (2021-2033)

11.1.2. Market Revenue and Volume Forecast, by Technology (2021-2033)

11.1.3. Market Revenue and Volume Forecast, by Product (2021-2033)

gChapter 12. Company Profiles

12.1. Roche Diagnostics

12.1.1. Company Overview

12.1.2. Product Offerings

12.1.3. Financial Performance

12.1.4. Recent Initiatives

12.2. Abbott Laboratories

12.2.1. Company Overview

12.2.2. Product Offerings

12.2.3. Financial Performance

12.2.4. Recent Initiatives

12.3. Thermo Fisher Scientific Inc.

12.3.1. Company Overview

12.3.2. Product Offerings

12.3.3. Financial Performance

12.3.4. Recent Initiatives

12.4. Illumina, Inc.

12.4.1. Company Overview

12.4.2. Product Offerings

12.4.3. Financial Performance

12.4.4. Recent Initiatives

12.5. Bio-Rad Laboratories, Inc.

12.5.1. Company Overview

12.5.2. Product Offerings

12.5.3. Financial Performance

12.5.4. Recent Initiatives

12.6. Myriad Genetics, Inc.

12.6.1. Company Overview

12.6.2. Product Offerings

12.6.3. Financial Performance

12.6.4. Recent Initiatives

12.7. Agilent Technologies, Inc.

12.7.1. Company Overview

12.7.2. Product Offerings

12.7.3. Financial Performance

12.7.4. Recent Initiatives

12.8. Danaher Corporation (Cepheid)

12.8.1. Company Overview

12.8.2. Product Offerings

12.8.3. Financial Performance

12.8.4. Recent Initiatives

12.9. Hologic, Inc.

12.9.1. Company Overview

12.9.2. Product Offerings

12.9.3. Financial Performance

12.9.4. Recent Initiatives

12.10. Foundation Medicine, Inc.

12.10.1. Company Overview

12.10.2. Product Offerings

12.10.3. Financial Performance

12.10.4. Recent Initiatives

Chapter 13. Research Methodology

13.1. Primary Research

13.2. Secondary Research

13.3. Assumptions

Chapter 14. Appendix

14.1. About Us

14.2. Glossary of Terms